US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Altamira Therapeutics Ltd. - Common Shares (NQ:CYTO)

0.3001 UNCHANGED
Last Price Updated: 3:55 PM EST, Dec 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altamira Therapeutics Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Altamira Therapeutics Provides Update on Nasdaq Listing
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news today! 
Via InvestorPlace
News headline image
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Hunting For Gains In Penny Stocks ↗
On Thursday, I saw that some penny stocks were already trading over 100 million shares, with others around 30 million. It was clear: penny stocks were in focus. Here’s how the trades went down. 
Via Talk Markets
News headline image
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire
News headline image
What's Going On With Altamira Therapeutics Stock? ↗
Altamira Therapeutics shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media... 
Via Benzinga
News headline image
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Earnings Scheduled For April 10, 2024 ↗
Companies Reporting Before The Bell • Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share on revenue of $12.55 billion. 
Via Benzinga
News headline image
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >